You just read:

Viking Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture in Plenary Oral Presentation at ASBMR 2018 Annual Meeting

News provided by

Viking Therapeutics, Inc.

Oct 01, 2018, 07:02 ET